Company news

Cloudbreak Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 6, 2026

Formation of an independent Special committee; delay in publication and despatch of 2026 interim report; and continued suspension of trading

September 30, 2026

List of directors and their roles and functions

September 23, 2026

Appointment of independent non-executive directors and continued suspension of trading

September 23, 2026

Business updates and supplemental announcement in relation to 2025 annual report

September 18, 2026

Suspension of trading

September 18, 2026

Cloudbreak Pharma Announces Results of First-of-Its-Kind Patient Survey on Pinguecula, Confirming Significant Unmet Need and Impact on Quality of Life

June 22, 2026

Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium

June 4, 2026

Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum

May 12, 2026

Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026

April 22, 2026

Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases

April 9, 2026

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

January 27, 2026

Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula

July 20, 2025

Decks